Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049533 | 0.91 | KMT2A (0.79) | KMT2AEPHX2CASP3HTTTLR2 | |
| SCHEMBL178687 | 0.87 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29397906 | 0.87 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29423575 | 0.87 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL19919104 | 0.87 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL30678051 | 0.86 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29511558 | 0.86 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL12734983 | 0.86 | KMT2A (0.72) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31652641 | 0.86 | KMT2A (0.75) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL34141 | 0.85 | KMT2A (0.70) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018039647-A1 | RNAI CONSTRUCTS FOR INHIBITING ASGR1 EXPRESSION AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2018-03-01 | — | — | WO | disclosed |